Golimumab (Simponi), taken with a drug called methotrexate, is recommended as a possible treatment for some adults with severe active rheumatoid arthritis in the same circumstances as other drugs for the condition1. They should be able to have golimumab if they have already tried other types of disease-modifying anti-rheumatic drugs (DMARDs), including a DMARD known as a tumour necrosis factor (or TNF for short) inhibitor, but these drugs haven’t worked and they cannot take rituximab therapy for medical reasons or because they had a bad reaction to it.

Treatment should be carried out by a specialist rheumatology team. After the first 6 months golimumab therapy can continue only if it is clearly improving the person’s rheumatoid arthritis. They should have check-ups every 6 months after that to make sure golimumab therapy is still working.

When assessing your rheumatoid arthritis, healthcare professionals should take into account any disabilities or difficulties in communicating you may have.

What does this mean for me?

If you have rheumatoid arthritis, and your doctor thinks that golimumab is the right treatment, you should be able to have the treatment on the NHS.

Golimumab should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking golimumab until you and your doctor decide it is the right time to stop.

This guidance has been updated by NICE technology appraisal guidance on adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375).

1 The circumstances described in this section are the same circumstances in which NICE recommends adalimumab, etanercept, infliximab, rituximab and abatacept.

  • National Institute for Health and Care Excellence (NICE) accreditation logo